LIMS database access: what reading it is worth, and what writing to it destroys
Laboratories ask for database access and usually mean one of two very different things: reading their own data for analysis, which is reasonable and useful, or writing to it directly, which bypasses every control the system exists to provide. This page separates them and covers the questions worth asking a vendor about what lies underneath.
- the access a laboratory should have to its own data layer
- read-only
- the electronic records rule the audit trail has to satisfy
- Part 11
- the accreditation whose records must survive an upgrade and a migration
- ISO 17025
Figures in this panel are the regulations and standards a laboratory system is built to satisfy, named from the regulations themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a software price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
What to ask about the data layer
- Ask for read access, and expect it through a view or an API. A read-only view or a documented interface gives you your data for analysis without exposing the internal schema you would then depend on. A vendor unwilling to provide any read route is a vendor whose data you cannot analyse, which is a real cost over a decade.
- Never write directly to the tables. Direct writes bypass validation, the audit trail and any business logic the application enforces, which means the record no longer reflects what the system believes happened. In a regulated laboratory that is a data integrity finding; in any laboratory it is a corruption waiting to be discovered.
- Establish how the audit trail is stored and whether it can be read. The audit trail is the part of the record an inspector reads, and its usefulness depends on whether it can be queried rather than only displayed a row at a time. Ask to see an audit trail extract for a real change.
- Ask what happens to old data on upgrade and on archive. Schemas change between major versions, and archived data that can only be read by a retired version is data you have lost. Ask specifically how historical records are migrated and whether an archive remains queryable.
- Confirm the export before you sign. A full export including the audit trail in an open format, tested during the evaluation, is the single most useful hour of a software trial. It decides whether you can ever leave, and therefore what every renewal conversation looks like.
Reporting against a copy rather than the live system
A nightly extract into a reporting store gives analysts freedom without putting query load on the system the laboratory depends on. It costs a little freshness and removes both the performance risk and the temptation to query production directly.
Define the extract's contents and its refresh with the people who will use it. An extract that omits the field somebody needs gets worked around, usually by asking for the access this page warns against.
Validation and the data layer
Where the work is regulated, the system is validated for its intended use and the validation covers the data it holds. A change to the data outside the application is a change outside the validated state, which is why direct writes are a finding rather than a shortcut.
Keep the validation documentation current through upgrades. A system validated at go-live and upgraded twice since is, on paper, an unvalidated system holding regulated records.
An ngs lims, and what a genomics laboratory needs from it
The unit of work in sequencing is not a sample but a library on a flow cell, and that is where a general laboratory system struggles: one sample becomes several libraries, libraries are pooled with indices that must not collide, a run yields files rather than results, and a re run has to be traceable to the same sample without becoming the same record.
So the requirements to write down are index management and collision checking, pooling and demultiplexing records, the link from a sample to the files and the pipeline version that produced them, and a re run that keeps its own identity. A system that models samples and results alone will end up with a spreadsheet beside it holding the pooling.
lims applications, and where the system is used
The same software is bought for very different settings, and each brings its own must-haves. A contract testing laboratory needs samples, tests, worklists and certificates. A manufacturing quality laboratory needs specifications, batch linkage and out-of-specification handling. A clinical laboratory needs patient identity, results interfaces and reporting rules. Research needs flexible experiments and links to instruments. Biobanking needs location, consent and chain of custody. Asking which application a vendor's deployments are in tells you more than any feature list, because the configuration effort follows the setting.
free lab notebook software and what the price excludes
free lab notebook software is genuinely useful for an individual and is usually limited where a laboratory needs support: audit trail completeness, export of everything in an open format, backup ownership and a migration path. The question to ask is what happens to the data if the service closes, since a notebook is a record that has to outlive the tool that made it.
data integrity compliance and what a system has to show
data integrity compliance means the record is attributable, legible, contemporaneous, original and accurate, and a system demonstrates it with user accounts that are never shared, an audit trail that cannot be switched off, time synchronisation and a backup that has been restored at least once. Most findings in this area are about the process around the software rather than the software.
process analytical technology pat, and what it changes
process analytical technology pat measures a quality attribute during manufacture instead of testing a sample afterwards, which is what allows real time release and a control strategy built on understanding rather than on end point checks. The work is in the model linking the measurement to the attribute, and in the validation of that model, not in the instrument.
Common questions
- Should I have direct access to the lims database?
- Read access, yes, ideally through a documented view or interface. Write access, no: direct writes bypass validation, business logic and the audit trail, and leave a record that does not describe what the system thinks happened.
- Who owns the schema?
- The vendor, in practice, and it changes between versions. That is why analysis should run against a stable view or an interface rather than against the internal tables, which can be reshaped by an upgrade without warning.
- What does the audit trail have to do?
- Record who changed what, when and why, be protected from alteration, and be readable. Under 21 CFR Part 11 it also has to be reviewed rather than merely enabled, which means it has to be queryable in practice.
- How do I get my data out at the end?
- Test the export during the trial, including the audit trail, in an open format. An export that turns out to be a set of screen reports is not an export, and discovering that at the end of a contract is the worst moment to discover it.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/lims-database/.